Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

304

Participants

Timeline

Start Date

May 23, 2016

Primary Completion Date

January 12, 2026

Study Completion Date

January 12, 2026

Conditions

Hodgkin Lymphoma

Interventions

BIOLOGICAL

pembrolizumab

IV infusion

BIOLOGICAL

brentuximab vedotin

IV infusion

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY